Antibody-drug conjugates are expanding from late-line to first-line combination regimens in lung cancer
New Drug Class Shifts Lung Cancer Treatment Toward First-Line Use
This narrative review examines the expanding role of antibody-drug conjugates (ADCs) in non-small cell lung cancer (NSCLC) and small cell lu…
A new class of cancer drugs is moving from last-resort treatment to first-line therapy for lung cancer, but early data need confirmation.
Serplulimab induced grade 4 checkpoint inhibitor pneumonitis in an elderly patient with SCLC and COPD
New cancer treatment causes severe lung inflammation in elderly patients
This case report describes a grade 4 serplulimab-induced checkpoint inhibitor pneumonitis in an 80-year-old man with extensive-stage small c…
A new cancer drug caused severe, life-threatening lung inflammation in an 80-year-old man with existing lung disease.
Later-line antibody-drug conjugates show 25.7% objective response rate in advanced small-cell lung cancer
Antibody-drug conjugates show activity in advanced small-cell lung cancer
This systematic review and meta-analysis evaluates later-line monotherapy with antibody-drug conjugates (ADCs) for advanced small-cell lung …
Antibody-drug conjugates show promise for treating advanced small-cell lung cancer, though they are associated with frequent clinical toxici…
Tarlatamab improves symptom and functional outcomes in extensive-stage small cell lung cancer
New trial shows tarlatamab improves symptoms for lung cancer patients
This Phase 3 randomized controlled trial of 509 adults with extensive-stage small cell lung cancer found that tarlatamab improved several pa…
A new trial shows tarlatamab helps patients with small cell lung cancer manage symptoms like coughing and chest pain better than standard ch…
Atezolizumab and lurbinectedin combinations show potential for superior progression-free survival in extensive-stage small cell lung cancer
New Drug Combos Show Promise for Aggressive Small Cell Lung Cancer
This Bayesian network meta-analysis of 18 regimens in treatment-nađve patients with extensive-stage small cell lung cancer suggests that ate…
A massive analysis of 8,945 patients points to two drug cocktails that may extend survival in extensive-stage small cell lung cancer.
Gut-lung axis in lung cancer: soluble metabolites lead, neural pathways remain hypothetical
Gut Health Links May Influence Lung Cancer Treatment Paths
This narrative review with a systematic search examined 168 studies on the gut-lung axis in non-small-cell and small-cell lung cancer. Solub…
New research explores how the gut-lung axis and specific metabolites might play a role in managing lung cancer treatments.
Nab-paclitaxel, cisplatin, and pembrolizumab achieved pathologic complete response in a patient with small cell lung cancer
New Treatment Approach Shows Success for a Rare Type of Lung Cancer
This case report describes a 61-year-old man with high-grade thoracic malignancy who achieved a pathologic complete response and undetectabl…
A 61-year-old man with a rare lung cancer showed a complete response after receiving a specific mix of drugs and surgery.
B7-H3-targeted ADCs achieve 54% objective response rate in previously treated small cell lung cancer
B7-H3 Targeted Drugs Show Promise for Small Cell Lung Cancer
This systematic review and meta-analysis evaluates B7-H3-targeted antibody-drug conjugates for patients with previously treated small cell l…
New data suggests B7-H3 targeted therapies may offer higher response rates than standard treatments for patients with small cell lung cancer…
First-line immune checkpoint inhibitor combinations improve overall survival in extensive-stage small-cell lung cancer
Immune checkpoint inhibitors combined with chemotherapy improve small cell lung cancer survival
This meta-analysis of 3,910 patients with extensive-stage small-cell lung cancer (ES-SCLC) found that first-line immune checkpoint inhibitor…
Combining immune checkpoint inhibitors with chemotherapy shows better survival rates for patients with extensive stage small cell lung cance…
Chemoradiotherapy combined with immunotherapy improves progression-free and overall survival in limited-stage small-cell lung cancer
Immunotherapy Combined With Chemoradiotherapy Shows Promise for Lung Cancer
This meta-analysis of randomized controlled trials evaluated the impact of chemoradiotherapy (CCRT) plus immunotherapy on 1,853 patients wit…
Adding immunotherapy to standard chemoradiotherapy shows a favorable trend in survival for patients with limited-stage small-cell lung cance…
Paclitaxel monotherapy shows modest activity in relapsed small cell lung cancer
Nab-paclitaxel shows similar results to paclitaxel for lung cancer
This meta-analysis examined paclitaxel monotherapy in relapsed small cell lung cancer. The 3-month progression-free survival rate was modest…
New data compares two types of paclitaxel treatments for relapsed small cell lung cancer, showing similar safety and effectiveness.
Nab-paclitaxel provides moderate efficacy and manageable safety for advanced or recurrent small cell lung cancer
Nab-paclitaxel shows moderate results for advanced small cell lung cancer
This meta-analysis of 334 patients with advanced or recurrent small cell lung cancer found nab-paclitaxel achieved an overall response rate …
A new analysis shows nab-paclitaxel offers manageable safety and steady results for patients with advanced small cell lung cancer.
Research across Extensive-Stage Small-Cell Lung Cancer
Related studies from across the Extensive-Stage Small-Cell Lung Cancer family.
EGFR p.E709_T710delinsD mutation may present with primary resistance and rapid progression on afatinib
Specific Lung Cancer Mutation May Lead to Rapid Treatment Failure
This case report and literature review describes a patient with stage IV lung adenocarcinoma and an EGFR p.E709_T710delinsD mutation who exp…
A specific mutation in lung cancer may cause patients to progress quickly on afatinib, highlighting the need for early monitoring and testin…
Pembrolizumab-induced hypophysitis can cause arginine vasopressin deficiency unmasked by glucocorticoid therapy
Pembrolizumab Treatment Linked to Rare Hormone Deficiency in Lung Cancer
This case report and review describes a patient with metastatic lung adenocarcinoma who developed hypophysitis after pembrolizumab monothera…
A rare case of lung cancer treatment revealed a complex hormone deficiency that only appeared after the patient received steroid therapy.
Toripalimab can induce myositis, myocarditis, and thyroiditis in patients with non-small cell lung cancer
Toripalimab Treatment Linked to Heart and Muscle Inflammation
This case report and literature review describes a 74-year-old male with stage IIIA lung squamous cell carcinoma who developed multiple immu…
A single case study shows a patient with lung cancer developed heart and muscle inflammation after receiving toripalimab treatment.
Icotinib treatment for EGFR-mutated NSCLC may be associated with rare treatment-related myeloid neoplasm
Icotinib Treatment for Lung Cancer Linked to Rare Blood Condition
This case report and literature review describes a 75-year-old female with lung adenocarcinoma treated with icotinib. The report identifies …
A rare case of acute myeloid leukemia was linked to a specific lung cancer treatment, highlighting the need for regular blood monitoring.
NLRP3 signaling and IL-1β inhibition show context-dependent roles in non-small cell lung cancer
IL-1β Inhibition Shows Potential in Non-Small Cell Lung Cancer
This narrative review synthesizes experimental and clinical data regarding NLRP3 signaling and IL-1β inhibition in non-small cell lung cance…
New research explores how blocking specific inflammatory pathways might influence the environment of non-small cell lung cancer.
First-line EGFR inhibitor options for advanced NSCLC require balancing efficacy with patient-centered tolerability trade-offs
New Treatment Options for Lung Cancer Patients with EGFR Mutations
This narrative review examines first-line therapy options for patients with advanced EGFR-mutated non-small cell lung cancer. The authors co…
Newer first-line therapies for lung cancer offer more options, but doctors must balance the strength of the drug against how well a patient …
miR-155 overexpression is frequently associated with treatment resistance across 8 cancer types
miR-155 Expression Linked to Treatment Resistance in Various Cancers
This systematic review of 19 studies across 8 cancer types indicates that miR-155 overexpression is associated with treatment resistance in …
Research suggests that high levels of a specific molecule, miR-155, may be linked to how well certain cancers respond to treatment.
PD-1/PD-L1 inhibitors with SRS or FSRT achieve 87% one-year local control in brain metastases
Combining immunotherapy and radiation for brain metastases shows promise
This meta-analysis of 2587 patients with brain metastases evaluated the combination of PD-1/PD-L1 inhibitors with stereotactic radiosurgery …
A new analysis shows that combining specific immunotherapy drugs with radiation can help control brain tumors and manage side effects.
TCM combined with EGFR-TKIs significantly improves progression-free survival in advanced EGFR-mutant NSCLC
Traditional Chinese medicine may improve survival for certain lung cancers
This meta-analysis evaluates the impact of traditional Chinese medicine (TCM) combined with EGFR-TKIs in patients with advanced EGFR-mutant …
Combining traditional Chinese medicine with targeted therapies may help patients with a specific type of lung cancer live longer without the…
mRNA vaccines provide a clinically validated platform to induce durable anti-tumor immunity in solid tumors
mRNA Vaccines Show Potential for Treating Several Solid Tumors
This systematic review evaluates mRNA vaccines for melanoma, pancreatic cancer, and non-small cell lung cancer. The authors conclude that mR…
mRNA technology is being used to create cancer vaccines that may help patients with melanoma, pancreatic, and lung cancers by building lasti…
Atezolizumab with SBRT fails to improve survival in early NSCLC
Trial shows atezolizumab plus SBRT does not improve lung cancer survival
Adding atezolizumab to stereotactic body radiotherapy did not improve overall survival in inoperable early-stage NSCLC, while increasing sev…
A large phase 3 trial found that adding the immunotherapy drug atezolizumab to SBRT did not improve survival for patients with inoperable lu…
Polygenic methylation patterns are linked to osimertinib resistance in non-small cell lung cancer
Methylation Patterns Linked to Drug Resistance in Lung Cancer
This systematic review examines the role of polygenic DNA and RNA methylation in osimertinib resistance for patients with non-small cell lun…
New research identifies how changes in DNA and RNA methylation may contribute to drug resistance in patients with non-small cell lung cancer…
Questions about Small Cell Lung Cancer
Does toripalimab plus anlotinib maintenance show promise for extensive-stage small-cell lung cancer?
Yes, a phase II trial found toripalimab plus anlotinib maintenance after first-line chemo led to median progression-free survival of 8.18 months and overall survival of 23.05 months in ES-SCLC.
Full answer →Do bispecific antibodies or CAR T-cell therapy treat advanced Small Cell Lung Cancer?
Yes, both bispecific antibodies and CAR T-cell therapy are being studied for advanced SCLC, with bispecific antibodies showing more clinical progress, especially tarlatamab targeting DLL3.
Full answer →Do immune checkpoint inhibitors improve survival for first-line Small Cell Lung Cancer treatment?
Yes, immune checkpoint inhibitors combined with chemotherapy improve survival as first-line treatment for extensive-stage small-cell lung cancer.
Full answer →All Small Cell Lung Cancer Articles
- Antibody-drug conjugates are expanding from late-line to first-line combination regimens in lung cancer
- Later-line antibody-drug conjugates show 25.7% objective response rate in advanced small-cell lung cancer
- Serplulimab induced grade 4 checkpoint inhibitor pneumonitis in an elderly patient with SCLC and COPD
- Tarlatamab improves symptom and functional outcomes in extensive-stage small cell lung cancer
- Atezolizumab and lurbinectedin combinations show potential for superior progression-free survival in extensive-stage small cell lung cancer
- Gut-lung axis in lung cancer: soluble metabolites lead, neural pathways remain hypothetical
- Nab-paclitaxel, cisplatin, and pembrolizumab achieved pathologic complete response in a patient with small cell lung cancer
- B7-H3-targeted ADCs achieve 54% objective response rate in previously treated small cell lung cancer
- First-line immune checkpoint inhibitor combinations improve overall survival in extensive-stage small-cell lung cancer
- Chemoradiotherapy combined with immunotherapy improves progression-free and overall survival in limited-stage small-cell lung cancer
- Paclitaxel monotherapy shows modest activity in relapsed small cell lung cancer
- Nab-paclitaxel provides moderate efficacy and manageable safety for advanced or recurrent small cell lung cancer
- Tislelizumab plus chemotherapy improves survival in extensive-stage small cell lung cancer
- Review of T cell engagers highlights potential for treating solid tumors and small cell lung cancer cases
- Early time-of-day immune checkpoint inhibitor administration improves overall survival in advanced solid tumors
- Toripalimab plus anlotinib maintenance shows promise in ES-SCLC after first-line chemo
- Meta-analysis shows platinum-etoposide plus PD-1/PD-L1 inhibitor improves survival in extensive-stage small-cell lung cancer
- Systematic review and meta-analysis shows immune checkpoint inhibitors improve survival in first-line ES-SCLC but not as single agents in second-line
- Review examines thoracic radiotherapy combined with chemoimmunotherapy for extensive-stage small cell lung cancer patients
- Magrolimab plus docetaxel shows limited efficacy in metastatic lung and urothelial cancers
- Review of 68Ga-Pentixafor PET/CT Utility in Lung Cancer Diagnosis and Management
- Narrative review summarizes bispecific antibodies and CAR T-cell therapy for advanced lung cancer
- In a phase 2 trial, [Ga]Ga-SSO120 PET/CT detected malignancies in 18 of 19 patients with small cell or large cell neuroendocrine lung cancer
- Phase II studies evaluate tislelizumab plus sitravatinib or anlotinib maintenance in extensive-stage small-cell lung cancer
- Phase I study finds amrubicin-cisplatin with radiotherapy feasible in limited-stage SCLC